Upstream Bio, Inc.
NMS: UPBLive Quote
📈 ZcoreAI Score
Our AI model analyzes Upstream Bio, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get UPB Z-Score →About Upstream Bio, Inc.
Healthcare
Biotechnology
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
📊 Fundamental Analysis
Upstream Bio, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 9.0% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is -35.4%, which indicates that capital utilization is currently under pressure.
At a current price of $10.49, UPB currently trades near the bottom of its 52-week range (12%), indicating potential value or weakness (Range: $7.22 - $33.68).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
⚠️
Revenue Growth
Moderate
🔴
Return on Equity
Weak
Key Financials
Market Cap
$570.87M
Trailing P/E
--
Forward P/E
-3.25
Beta (5Y)
--
52W High
$33.68
52W Low
$7.22
Avg Volume
1.33M
Day High
Day Low